Kemberly Center, NP
Family · Calhoun, GANPI 1508454604
Payments from drug & device makers
Across 168 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$400
- Lilly USA, LLC$260
- Boehringer Ingelheim$236
- Novo Nordisk$215
- Bayer$197
- Amgen$181
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,601100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 38 | $400 |
| Lilly USA, LLC | 19 | $260 |
| Boehringer Ingelheim | 13 | $236 |
| Novo Nordisk | 11 | $215 |
| Bayer | 11 | $197 |
| Amgen | 13 | $181 |
| Exact Sciences | 10 | $179 |
| Pfizer | 8 | $151 |
| AstraZeneca | 7 | $101 |
| Dexcom, Inc. | 5 | $90 |
| Xeris Pharmaceuticals, Inc. | 5 | $85 |
| GSK | 5 | $84 |
| Vanda Pharmaceuticals Inc. | 3 | $69 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $46 |
| Cranial Technologies, Inc | 2 | $33 |
| Abbott | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Esperion Therapeutics, Inc. | 1 | $25 |
| Johnson & Johnson | 2 | $24 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Almatica Pharma LLC | 1 | $12 |
How this compares
$2,601 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 107 | $97,572 |
| TrulicityDulaglutide | 40 | $40,000 |
| OzempicSemaglutide | 29 | $35,066 |
| EliquisApixaban | 34 | $27,402 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $13,292 |
| LinzessLinaclotide | 16 | $9,876 |
| XareltoRivaroxaban | 16 | $8,838 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $3,792 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $3,154 |
| Gabapentin | 99 | $1,949 |
| Atorvastatin Calcium | 227 | $1,535 |
| Levothyroxine Sodium | 163 | $1,263 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 21 | $924 |
| Buspirone Hcl | 33 | $775 |
| Lisinopril | 137 | $713 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $236 | $97,572107 claims |
| Lilly USA, LLCTrulicity | $260 | $40,00040 claims |
| Novo NordiskOzempic | $215 | $35,06629 claims |
| PfizerEliquis | $151 | $27,40234 claims |
| GSKTrelegy Ellipta | $84 | $13,29213 claims |
| AbbVieLinzess | $400 | $9,87616 claims |
| Johnson & JohnsonXarelto | $24 | $8,83816 claims |
| Almatica Pharma LLCSertraline Hcl | $12 | $30453 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.
Other family in Calhoun
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.